Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
James F. Howard, Kimiaki Utsugisawa, Michael Benatar, et al.·2017·The Lancet Neurology